AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 35779669 — intervention group
Group type: EXPERIMENTAL
Intervention: Cubans/Dominicans (C&D)
Number of subjects: 598
Study 35780090 — intervention group
Group type: EXPERIMENTAL
Intervention: Primary care physician actions at initial visit for adolescents with suicidal risk
Number of subjects: 200
Study 35780090 — intervention group
Group type: EXPERIMENTAL
Intervention: Reporting of active suicidal ideation, past suicide attempts, referrals to behavioral health counseling, and diagnosis of depression
Number of subjects: 200
Study 35780090 — intervention group
Group type: EXPERIMENTAL
Intervention: Asking about weapons in the home
Number of subjects: 200
Study 35780090 — intervention group
Group type: EXPERIMENTAL
Intervention: Asking about safety plans
Number of subjects: 200
Study 35780090 — intervention group
Group type: EXPERIMENTAL
Intervention: Follow-up for adolescents with a history of suicide concerns
Number of subjects: 200
Study 35780090 — intervention group
Group type: EXPERIMENTAL
Intervention: Need for national guidelines regarding primary care follow-up of youth with suicide concerns
Number of subjects: 200
Study 35780092 — intervention group
Group type: EXPERIMENTAL
Intervention: Norepinephrine infusion
Number of subjects: 28
Study 35780092 — intervention group
Group type: EXPERIMENTAL
Intervention: Norepinephrine infusion in SOMATO-treated patients
Number of subjects: 28
Study 35780092 — intervention group
Group type: EXPERIMENTAL
Intervention: Norepinephrine infusion in SOMATO-untreated patients
Number of subjects: 28
Study 35780095 — intervention group
Group type: EXPERIMENTAL
Intervention: ePRO follow-up pathway with automated 3-monthly reminders for ePRO questionnaire and blood tests.
Number of subjects: 24
Study 35780095 — intervention group
Group type: EXPERIMENTAL
Intervention: ePRO follow-up pathway
Number of subjects: 24
Study 35780200 — intervention group
Group type: EXPERIMENTAL
Intervention: sBAFF
Number of subjects: 100
Study 35780200 — intervention group
Group type: EXPERIMENTAL
Intervention: sAPRIL
Number of subjects: 100
Study 35780200 — intervention group
Group type: EXPERIMENTAL
Intervention: sBAFF and sAPRIL correlation
Number of subjects: 100
Study 35780243 — intervention group
Group type: EXPERIMENTAL
Intervention: Troriluzole (BHV-4157) 420 mg total daily dose in combination with nivolumab 240 mg IV every 2 weeks
Number of subjects: 14
Study 35780243 — intervention group
Group type: EXPERIMENTAL
Intervention: Troriluzole monotherapy (lead-in period)
Number of subjects: 14
Study 35781099 — intervention group
Group type: EXPERIMENTAL
Intervention: Belumosudil (oral rho-associated coiled-coil-containing protein kinase-2 (ROCK2) inhibitor)
Number of subjects: 170
Study 35781166 — intervention group
Group type: EXPERIMENTAL
Intervention: Pembrolizumab plus lenvatinib (PL)
Number of subjects: 697
Study 35781166 — intervention group
Group type: COMPARATOR
Intervention: Chemotherapy
Number of subjects: 697
Study 35781776 — intervention group
Group type: EXPERIMENTAL
Intervention: Stratified medical therapy based on the type of INOCA
Number of subjects: 0
Study 35781776 — intervention group
Group type: EXPERIMENTAL
Intervention: Intensive medical therapy
Number of subjects: 0
Study 35781807 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive behavioral therapy (CBT)
Number of subjects: 80
Study 35782623 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral lucerastat twice daily for 6 months
Number of subjects: 118
Study 35782623 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 118
Study 35782751 — intervention group
Group type: EXPERIMENTAL
Intervention: Paclitaxel (80 mg/m2)
Number of subjects: 0
Study 35782751 — intervention group
Group type: EXPERIMENTAL
Intervention: Regorafenib and paclitaxel
Number of subjects: 0
Study 35782928 — intervention group
Group type: EXPERIMENTAL
Intervention: Mediterranean Diet
Number of subjects: 523
Study 35782928 — intervention group
Group type: COMPARATOR
Intervention: Low-fat Diet
Number of subjects: 523
Study 35782954 — intervention group
Group type: EXPERIMENTAL
Intervention: Prebiotic fiber supplement (12 g daily)
Number of subjects: 20
Study 35782954 — intervention group
Group type: COMPARATOR
Intervention: Placebo (12 g daily)
Number of subjects: 20
Study 35783246 — intervention group
Group type: EXPERIMENTAL
Intervention: Anti-inflammatory treatment
Number of subjects: 2008
Study 35783246 — intervention group
Group type: EXPERIMENTAL
Intervention: Two subphenotypes identified
Number of subjects: 2008
Study 35783246 — intervention group
Group type: EXPERIMENTAL
Intervention: Operative mortality
Number of subjects: 2008
Study 35783246 — intervention group
Group type: EXPERIMENTAL
Intervention: Subphenotype frequency
Number of subjects: 2008
Study 35783610 — intervention group
Group type: EXPERIMENTAL
Intervention: Convalescent plasma therapy
Number of subjects: 104
Study 35783610 — intervention group
Group type: COMPARATOR
Intervention: Control group (no convalescent plasma therapy)
Number of subjects: 104
Study 35783648 — intervention group
Group type: EXPERIMENTAL
Intervention: Pirfenidone
Number of subjects: 0
Study 35783648 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 35783649 — intervention group
Group type: EXPERIMENTAL
Intervention: Quality improvement care bundle for the management of acute spontaneous intracerebral hemorrhage (ICH)
Number of subjects: 0
Study 35783649 — intervention group
Group type: EXPERIMENTAL
Intervention: Care bundle integration into routine care
Number of subjects: 0
Study 35783686 — intervention group
Group type: EXPERIMENTAL
Intervention: Screening for sexually transmitted infections (STIs) using an in-house polymerase chain reaction panel.
Number of subjects: 148
Study 35783822 — intervention group
Group type: EXPERIMENTAL
Intervention: Colchicine 0.6 mg po twice daily for 30 days plus standard of care
Number of subjects: 93
Study 35783822 — intervention group
Group type: COMPARATOR
Intervention: Standard of care alone
Number of subjects: 93
Study 35783836 — intervention group
Group type: EXPERIMENTAL
Intervention: High-Intensity Interval Training (HIIT) for 9 weeks
Number of subjects: 73
Study 35783836 — intervention group
Group type: COMPARATOR
Intervention: Moderate-Intensity Continuous Training (MICT) for 9 weeks
Number of subjects: 73
Study 35783836 — intervention group
Group type: EXPERIMENTAL
Intervention: High-Intensity Interval Training (HIIT)
Number of subjects: 73
Study 35783836 — intervention group
Group type: COMPARATOR
Intervention: Moderate-Intensity Continuous Training (MICT)
Number of subjects: 73
Study 35784017 — intervention group
Group type: EXPERIMENTAL
Intervention: Knee Pain (KP)
Number of subjects: 2832
Study 35784017 — intervention group
Group type: EXPERIMENTAL
Intervention: Paracetamol and opioids
Number of subjects: 2832
Study 35784017 — intervention group
Group type: EXPERIMENTAL
Intervention: NSAIDs
Number of subjects: 2832
Study 35784017 — intervention group
Group type: COMPARATOR
Intervention: Controls without KP or knee OA
Number of subjects: 2832
Study 35784538 — intervention group
Group type: EXPERIMENTAL
Intervention: High admission blood glucose (ABG) group
Number of subjects: 6892
Study 35784538 — intervention group
Group type: COMPARATOR
Intervention: Low admission blood glucose (ABG) group
Number of subjects: 6892
Study 35784545 — intervention group
Group type: EXPERIMENTAL
Intervention: Thyroid hormone sensitivity (measured by TSHI, TFQI, TSHI, TT4RI, PTFQI, FT3/FT4)
Number of subjects: 30244
Study 35784545 — intervention group
Group type: EXPERIMENTAL
Intervention: Thyroid hormone sensitivity (in females)
Number of subjects: 30244
Study 35784545 — intervention group
Group type: EXPERIMENTAL
Intervention: Thyroid hormone sensitivity (in patients aged over 60 years)
Number of subjects: 30244
Study 35784546 — intervention group
Group type: EXPERIMENTAL
Intervention: Berberine (BBR) alone
Number of subjects: 240
Study 35784546 — intervention group
Group type: EXPERIMENTAL
Intervention: Inulin plus Berberine (BBR)
Number of subjects: 240
Study 35784546 — intervention group
Group type: EXPERIMENTAL
Intervention: Inulin alone
Number of subjects: 240
Study 35784546 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 240
Study 35784580 — intervention group
Group type: EXPERIMENTAL
Intervention: Decreasing dietary salt intake
Number of subjects: 1090
Study 35784580 — intervention group
Group type: EXPERIMENTAL
Intervention: Steadily low dietary salt intake
Number of subjects: 1090
Study 35784580 — intervention group
Group type: COMPARATOR
Intervention: Increasing dietary salt intake
Number of subjects: 1090
Study 35784580 — intervention group
Group type: COMPARATOR
Intervention: Steadily medium dietary salt intake
Number of subjects: 1090
Study 35784580 — intervention group
Group type: COMPARATOR
Intervention: Steadily high dietary salt intake
Number of subjects: 1090
Study 35784641 — intervention group
Group type: EXPERIMENTAL
Intervention: Adipose-derived MSC infusions (1 × 10)
Number of subjects: 10
Study 35784641 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 10
Study 35785107 — intervention group
Group type: EXPERIMENTAL
Intervention: Transcervical fibroid ablation (TFA) with the Sonata System
Number of subjects: 28
Study 35785613 — intervention group
Group type: EXPERIMENTAL
Intervention: Peer support services integrated into primary care for OUD treatment.
Number of subjects: 2700000
Study 35785613 — intervention group
Group type: COMPARATOR
Intervention: Buprenorphine treatment for OUD.
Number of subjects: 2700000
Study 35785621 — intervention group
Group type: EXPERIMENTAL
Intervention: Dabigatran, Rivaroxaban, Apixaban (DOACs)
Number of subjects: 478
Study 35786528 — intervention group
Group type: EXPERIMENTAL
Intervention: Baricitinib (janus kinase inhibitor)
Number of subjects: 142
Study 35786528 — intervention group
Group type: COMPARATOR
Intervention: Not applicable (pre-treatment values)
Number of subjects: 142
Study 35786544 — intervention group
Group type: EXPERIMENTAL
Intervention: Deep neural network (DNN) using accelerometry (ACC) and photoplethysmography (PPG) signals
Number of subjects: 301
Study 35786544 — intervention group
Group type: EXPERIMENTAL
Intervention: Deep neural network (DNN) using wrist-worn CST data
Number of subjects: 301
Study 35786544 — intervention group
Group type: COMPARATOR
Intervention: Spectral preprocessing
Number of subjects: 301
Study 35786544 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of ACC and PPG modalities
Number of subjects: 301
Study 35786544 — intervention group
Group type: EXPERIMENTAL
Intervention: Increasing input segment size to 1024 epochs (∼8.5 hrs.)
Number of subjects: 301
Study 35786738 — intervention group
Group type: EXPERIMENTAL
Intervention: Biliary stenting
Number of subjects: 211
Study 35786738 — intervention group
Group type: COMPARATOR
Intervention: T-tube drainage
Number of subjects: 211
Study 35786738 — intervention group
Group type: COMPARATOR
Intervention: Primary closure
Number of subjects: 211
Study 35786777 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuous Glucose Monitoring (CGM) using Dexcom G6 device
Number of subjects: 10
Study 35786777 — intervention group
Group type: COMPARATOR
Intervention: Matched healthy volunteers
Number of subjects: 10
Study 35787017 — intervention group
Group type: EXPERIMENTAL
Intervention: Bone marrow biopsies (BMB) before/after therapy
Number of subjects: 580
Study 35787017 — intervention group
Group type: EXPERIMENTAL
Intervention: Bone marrow biopsies (BMB)
Number of subjects: 580
Study 35787273 — intervention group
Group type: EXPERIMENTAL
Intervention: PREVENT intervention sites
Number of subjects: 158
Study 35787273 — intervention group
Group type: COMPARATOR
Intervention: Control sites
Number of subjects: 158
Study 35787726 — intervention group
Group type: EXPERIMENTAL
Intervention: ICU admission
Number of subjects: 4041
Study 35787784 — intervention group
Group type: EXPERIMENTAL
Intervention: PI3Kα inhibitor alpelisib
Number of subjects: 0
Study 35787807 — intervention group
Group type: EXPERIMENTAL
Intervention: Laparoscopic guided minilaparotomy
Number of subjects: 112
Study 35787831 — intervention group
Group type: EXPERIMENTAL
Intervention: edoxaban (3-month treatment)
Number of subjects: 100
Study 35788016 — intervention group
Group type: EXPERIMENTAL
Intervention: BMI_GDM CatBoost model
Number of subjects: 561
Study 35788016 — intervention group
Group type: EXPERIMENTAL
Intervention: ppBMI CatBoost model
Number of subjects: 561
Study 35788016 — intervention group
Group type: EXPERIMENTAL
Intervention: BMI_2hour CatBoost model
Number of subjects: 561
Study 35788016 — intervention group
Group type: EXPERIMENTAL
Intervention: BMI_Fasting CatBoost model
Number of subjects: 561
Study 35788016 — intervention group
Group type: EXPERIMENTAL
Intervention: BMI_GDM2 CatBoost model
Number of subjects: 561
Study 35788016 — intervention group
Group type: EXPERIMENTAL
Intervention: Total gestational weight gain
Number of subjects: 561
Study 35788031 — intervention group
Group type: EXPERIMENTAL
Intervention: Portable MRI examinations
Number of subjects: 14
Study 35788100 — intervention group
Group type: EXPERIMENTAL
Intervention: Cook for Your Life website (online nutrition resource)
Number of subjects: 2665
Study 35788116 — intervention group
Group type: EXPERIMENTAL
Intervention: 68Ga-grazytracer PET imaging
Number of subjects: 5
Study 35788195 — intervention group
Group type: EXPERIMENTAL
Intervention: Modified FRENCH scale (combining ECG and cardiovascular risk factors)
Number of subjects: 505
Study 35788195 — intervention group
Group type: EXPERIMENTAL
Intervention: Modified FRENCH scale (using CVRF collected by ED physicians)
Number of subjects: 505
Study 35788195 — intervention group
Group type: COMPARATOR
Intervention: Standard FRENCH scale (ECG-based)
Number of subjects: 505
Study 35788251 — intervention group
Group type: EXPERIMENTAL
Intervention: Comorbidities including type 2 diabetes mellitus, alcoholic liver disease, hyperthyroidism, gastrointestinal bleeding, hepatic encephalopathy (HE), and hepatorenal syndrome.
Number of subjects: 2166
Study 35788251 — intervention group
Group type: EXPERIMENTAL
Intervention: Presence of spontaneous bacterial peritonitis, pneumonia, and hepatic encephalopathy (HE).
Number of subjects: 2166
Study 35788251 — intervention group
Group type: EXPERIMENTAL
Intervention: Knowledge of risk factors for HBV-ACLF.
Number of subjects: 2166
Study 35788366 — intervention group
Group type: EXPERIMENTAL
Intervention: Dimensional Anhedonia Rating Scale (DARS)
Number of subjects: 533
Study 35788366 — intervention group
Group type: EXPERIMENTAL
Intervention: Lasso regression analysis
Number of subjects: 533
Study 35788366 — intervention group
Group type: COMPARATOR
Intervention: Healthy controls
Number of subjects: 533
Study 35788562 — intervention group
Group type: EXPERIMENTAL
Intervention: Presence of anti-IFN IgG
Number of subjects: 103
Study 35788722 — intervention group
Group type: EXPERIMENTAL
Intervention: Niraparib 200 mg once daily in 28-day cycles
Number of subjects: 21
Study 35788749 — intervention group
Group type: EXPERIMENTAL
Intervention: Cervical lesion proportion (CLP) measure using a digital imaging technique
Number of subjects: 70
Study 35788749 — intervention group
Group type: EXPERIMENTAL
Intervention: Rubbery papule count (RPC)
Number of subjects: 70
Study 35788913 — intervention group
Group type: EXPERIMENTAL
Intervention: Training intervention (face-to-face workshops or self-paced e-learning modules)
Number of subjects: 1484
Study 35788913 — intervention group
Group type: EXPERIMENTAL
Intervention: Training intervention
Number of subjects: 1484
Study 35789068 — intervention group
Group type: EXPERIMENTAL
Intervention: Chemotherapy alone (most common treatment regimen, 24.8%)
Number of subjects: 231
Study 35789068 — intervention group
Group type: EXPERIMENTAL
Intervention: Stage IIIA with curative surgery and resectable tumours
Number of subjects: 231
Study 35789068 — intervention group
Group type: EXPERIMENTAL
Intervention: Stage IIIB with ECOG score of 0/1, female gender, resectable tumours, adenocarcinoma, and curative surgery
Number of subjects: 231
Study 35789124 — intervention group
Group type: EXPERIMENTAL
Intervention: Fecal calprotectin (FC) measurement using LIAISON
Number of subjects: 0
Study 35789124 — intervention group
Group type: EXPERIMENTAL
Intervention: Machine learning algorithm including FC measurement
Number of subjects: 0
Study 35789261 — intervention group
Group type: EXPERIMENTAL
Intervention: Tenofovir disoproxil fumarate (TDF) therapy during late pregnancy
Number of subjects: 157
Study 35789261 — intervention group
Group type: COMPARATOR
Intervention: Untreated mothers
Number of subjects: 157
Study 35789261 — intervention group
Group type: EXPERIMENTAL
Intervention: Maternal HBV DNA titer
Number of subjects: 157
Study 35789261 — intervention group
Group type: EXPERIMENTAL
Intervention: Maternal genotype C
Number of subjects: 157
Study 35789261 — intervention group
Group type: EXPERIMENTAL
Intervention: Pre-S1 wild-type sequence
Number of subjects: 157
Study 35789593 — intervention group
Group type: EXPERIMENTAL
Intervention: Dietary Antioxidants
Number of subjects: 0
Study 35789593 — intervention group
Group type: COMPARATOR
Intervention: Control group (without Type 1 Diabetes)
Number of subjects: 0
Study 35789594 — intervention group
Group type: EXPERIMENTAL
Intervention: JOTROL (a highly bioavailable resveratrol preparation)
Number of subjects: 0
Study 35790108 — intervention group
Group type: EXPERIMENTAL
Intervention: Recent trials (2002-2016)
Number of subjects: 114
Study 35790108 — intervention group
Group type: COMPARATOR
Intervention: Old trials (1980-2002)
Number of subjects: 114
Study 35790143 — intervention group
Group type: EXPERIMENTAL
Intervention: Blinatumomab (9-28 μg/day for adults; 5-15 μg/m2/day for pediatrics)
Number of subjects: 31
Study 35790143 — intervention group
Group type: EXPERIMENTAL
Intervention: Blinatumomab
Number of subjects: 31
Study 35790315 — intervention group
Group type: EXPERIMENTAL
Intervention: Ceralasertib (240 mg two times a day) plus durvalumab (1500 mg) every 4 weeks
Number of subjects: 31
Study 35790332 — intervention group
Group type: EXPERIMENTAL
Intervention: Neotree e-health solution (android app with data visualisation)
Number of subjects: 15000
Study 35790332 — intervention group
Group type: EXPERIMENTAL
Intervention: Neotree clinical decision support algorithms
Number of subjects: 15000
Study 35790333 — intervention group
Group type: EXPERIMENTAL
Intervention: Opioid analgesics
Number of subjects: 1550
Study 35790333 — intervention group
Group type: EXPERIMENTAL
Intervention: Patient-centred health data aggregating platform
Number of subjects: 1550
Study 35790334 — intervention group
Group type: EXPERIMENTAL
Intervention: Experience of violence when using the toilet
Number of subjects: 1798
Study 35790334 — intervention group
Group type: EXPERIMENTAL
Intervention: Experience of violence when collecting water
Number of subjects: 1798
Study 35790334 — intervention group
Group type: EXPERIMENTAL
Intervention: Worry about violence when using the toilet
Number of subjects: 1798
Study 35790334 — intervention group
Group type: EXPERIMENTAL
Intervention: Worry about violence when collecting water
Number of subjects: 1798
Study 35790423 — intervention group
Group type: EXPERIMENTAL
Intervention: Motor features assessment in symptomatic participants with f-FTLD
Number of subjects: 184
Study 35790459 — intervention group
Group type: EXPERIMENTAL
Intervention: Not available
Number of subjects: 0
Study 35790566 — intervention group
Group type: EXPERIMENTAL
Intervention: Portal- and hepatic-vein embolization (PVE/HVE)
Number of subjects: 0
Study 35790584 — intervention group
Group type: EXPERIMENTAL
Intervention: High-frame-rate contrast-enhanced ultrasound particle image velocimetry (HFR CEUS PIV)
Number of subjects: 21
Study 35790651 — intervention group
Group type: EXPERIMENTAL
Intervention: Antifibrotic therapy (specifics not provided)
Number of subjects: 0
Study 35790816 — intervention group
Group type: EXPERIMENTAL
Intervention: Avapritinib
Number of subjects: 317
Study 35790816 — intervention group
Group type: COMPARATOR
Intervention: Best Available Therapy (BAT)
Number of subjects: 317
Study 35791008 — intervention group
Group type: EXPERIMENTAL
Intervention: Supra-marginal resection (extending 1 cm beyond the enhancing tumor)
Number of subjects: 72
Study 35791008 — intervention group
Group type: EXPERIMENTAL
Intervention: Supra-marginal resection
Number of subjects: 72
Study 35791008 — intervention group
Group type: COMPARATOR
Intervention: Standard gross total resection (GTR)
Number of subjects: 72
Study 35791026 — intervention group
Group type: EXPERIMENTAL
Intervention: High-intensity technology-assisted training (4-week program, 3 to 5 days per week, at least 5 sessions of 45 minutes each)
Number of subjects: 14
Study 35791026 — intervention group
Group type: EXPERIMENTAL
Intervention: High-intensity technology-assisted training
Number of subjects: 14
Study 35791625 — intervention group
Group type: EXPERIMENTAL
Intervention: semaglutide 2.4 mg single-dose pen-injector
Number of subjects: 0
Study 35791694 — intervention group
Group type: EXPERIMENTAL
Intervention: Temozolomide
Number of subjects: 0
Study 35792924 — intervention group
Group type: EXPERIMENTAL
Intervention: PegaGen (pegfilgrastim) administered once per cycle, with a single 6 mg dose injected in 99.17% of cycles.
Number of subjects: 654
Study 35793677 — intervention group
Group type: EXPERIMENTAL
Intervention: mAbs (bamlanivimab)
Number of subjects: 67
Study 35793677 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 67
Study 35793869 — intervention group
Group type: EXPERIMENTAL
Intervention: Bacterial burden in tumor cells
Number of subjects: 12
Study 35793869 — intervention group
Group type: EXPERIMENTAL
Intervention: Bacterial burden
Number of subjects: 12
Study 35793869 — intervention group
Group type: EXPERIMENTAL
Intervention: Expression of oncogenic β-catenin
Number of subjects: 12
Study 35793869 — intervention group
Group type: EXPERIMENTAL
Intervention: Intratumor bacteria
Number of subjects: 12
Study 35793925 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of HPV E4 and p16
Number of subjects: 500
Study 35793990 — intervention group
Group type: EXPERIMENTAL
Intervention: DA-8010 5 mg
Number of subjects: 306
Study 35793990 — intervention group
Group type: EXPERIMENTAL
Intervention: DA-8010 2.5 mg
Number of subjects: 306
Study 35793990 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 306
Study 35793990 — intervention group
Group type: COMPARATOR
Intervention: Solifenacin 5 mg
Number of subjects: 306
Study 35794298 — intervention group
Group type: EXPERIMENTAL
Intervention: Pre-pandemic assessments of anxiety and depression
Number of subjects: 81
Study 35794298 — intervention group
Group type: EXPERIMENTAL
Intervention: Pandemic-related stress
Number of subjects: 81
Study 35794298 — intervention group
Group type: EXPERIMENTAL
Intervention: Threat processing fMRI task pre-pandemic
Number of subjects: 81
Study 35794314 — intervention group
Group type: EXPERIMENTAL
Intervention: Video calls
Number of subjects: 64
Study 35794314 — intervention group
Group type: COMPARATOR
Intervention: Phone calls
Number of subjects: 64
Study 35794343 — intervention group
Group type: EXPERIMENTAL
Intervention: BACE inhibitor verubecestat
Number of subjects: 0
Study 35794343 — intervention group
Group type: EXPERIMENTAL
Intervention: Baseline SUVr values
Number of subjects: 0
Study 35794614 — intervention group
Group type: EXPERIMENTAL
Intervention: Regional anesthesia techniques (specifically double injection erector spinae plane block)
Number of subjects: 221